GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Gross-Profit-to-Asset %

Oncodesign Precision Medicine (XPAR:ALOPM) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2024)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Oncodesign Precision Medicine's annualized Gross Profit for the quarter that ended in Dec. 2024 was €0.00 Mil. Oncodesign Precision Medicine's average Total Assets over the quarter that ended in Dec. 2024 was €10.71 Mil. Therefore, Oncodesign Precision Medicine's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 was 0.00%.

Oncodesign Precision Medicine Gross-Profit-to-Asset % Historical Data

The historical data trend for Oncodesign Precision Medicine's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Gross-Profit-to-Asset % Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Gross-Profit-to-Asset %
-37.89 -19.04 3.44 -37.70 -46.04

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Gross-Profit-to-Asset % Get a 7-Day Free Trial 58.24 -37.67 -43.77 -32.47 -

Competitive Comparison of Oncodesign Precision Medicine's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Oncodesign Precision Medicine's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncodesign Precision Medicine's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's Gross-Profit-to-Asset % falls into.


;
;

Oncodesign Precision Medicine Gross-Profit-to-Asset % Calculation

Oncodesign Precision Medicine's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Dec. 2024 )/( (Total Assets (A: Dec. 2023 )+Total Assets (A: Dec. 2024 ))/ count )
=-6.294/( (16.632+10.711)/ 2 )
=-6.294/13.6715
=-46.04 %

Oncodesign Precision Medicine's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2024 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2024 )/( (Total Assets (Q: Jun. 2024 )+Total Assets (Q: Dec. 2024 ))/ count )
=0/( (0+10.711)/ 1 )
=0/10.711
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is two times the semi-annual (Dec. 2024) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Oncodesign Precision Medicine Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Gross-Profit-to-Asset %
Comparable Companies
XPAR:ALTME XPAR:ALTAO XPAR:ALVIO XPAR:ALINT XPAR:ALBPS XPAR:ALTHX XPAR:ALPAT XPAR:ALMDP XPAR:ALNEV XPAR:ALNFL VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Website
https://www.opm.oncodesign.com
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine Headlines

No Headlines